[Evaluation of cefotetan in pediatrics]

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases

Context:

• Pediatric infections pose significant health challenges.
• Cefotetan (CTT) is a cephalosporin antibiotic.
• Evaluating CTT's efficacy and safety in pediatric populations is crucial.

Purpose:

• To assess the clinical efficacy and safety of cefotetan (CTT) in treating pediatric infections.
• To determine the pharmacokinetic profile of CTT in children.

Summary:

• Pharmacokinetic studies showed mean serum concentrations of CTT decreasing from 204 mcg/ml at 15 minutes to 10 mcg/ml at 480 minutes post-intravenous injection (20 mg/kg), with a half-life of 2.18 hours and 68.3% urinary excretion within 8 hours.
• In vitro studies indicated CTT possesses greater antimicrobial activity against E. coli, H. influenzae, and K. pneumoniae compared to CEZ and CMZ.
• Clinical trials involving 22 pediatric patients with pneumonia, bronchopneumonia, acute tonsillitis, and urinary tract infections resulted in an overall efficacy rate of 95% when administered at 30 mg/kg every 12 hours.

Impact:

• CTT is a potentially effective antibiotic for pediatric infections.
• The study supports the use of CTT in pediatric patients, with a favorable safety profile observed.
• Further research may establish CTT as a standard treatment option for specific pediatric infections.